Literature DB >> 27473821

Histamine prevents radiation-induced mesenchymal changes in breast cancer cells.

Tamara E Galarza1, Nora A Mohamad1, Mónica A Táquez Delgado1, Guadalupe M Vedoya1, Ernesto J Crescenti2, Rosa M Bergoc3, Gabriela A Martín4, Graciela P Cricco5.   

Abstract

Radiotherapy is a prime option for treatment of solid tumors including breast cancer though side effects are usually present. Experimental evidence shows an increase in invasiveness of several neoplastic cell types through conventional tumor irradiation. The induction of epithelial to mesenchymal transition is proposed as an underlying cause of metastasis triggered by gamma irradiation. Experiments were conducted to investigate the role of histamine on the ionizing radiation-induced epithelial to mesenchymal transition events in breast cancer cells with different invasive phenotype. We also evaluated the potential involvement of Src phosphorylation in the migratory capability of irradiated cells upon histamine treatment. MCF-7 and MDA-MB-231 mammary tumor cells were exposed to a single dose of 2Gy of gamma radiation and five days after irradiation mesenchymal-like phenotypic changes were observed by optical microscope. The expression and subcellular localization of E-cadherin, β-catenin, vimentin and Slug were determined by immunoblot and indirect immunofluorescence. There was a decrease in the epithelial marker E-cadherin expression and an increase in the mesenchymal marker vimentin after irradiation. E-cadherin and β-catenin were mainly localized in cytoplasm. Slug positive nuclei, matrix metalloproteinase-2 activity and cell migration and invasion were significantly increased. In addition, a significant enhancement in Src phosphorylation/activation could be determined by immunoblot in irradiated cells. MCF-7 and MDA-MB-231 cells also received 1 or 20μM histamine during 24h previous to be irradiated. Notably, pre-treatment of breast cancer cells with 20μM histamine prevented the mesenchymal changes induced by ionizing radiation and also reduced the migratory behavior of irradiated cells decreasing phospho-Src levels. Collectively, our results suggest that histamine may block events related to epithelial to mesenchymal transition in irradiated mammary cancer cells and open a perspective for the potential use of histamine to improve radiotherapy efficacy.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Epithelial to mesenchymal transition; Histamine; Histamine (PubChem CID: 774); Ionizing radiation; PP2 (PubChem CID: 4878); Src

Mesh:

Substances:

Year:  2016        PMID: 27473821     DOI: 10.1016/j.phrs.2016.07.039

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  5 in total

Review 1.  Histamine receptors and cancer pharmacology: an update.

Authors:  Noelia A Massari; Melisa B Nicoud; Vanina A Medina
Journal:  Br J Pharmacol       Date:  2018-12-13       Impact factor: 8.739

2.  Cadmium stimulates metastasis-associated phenotype in triple-negative breast cancer cells through integrin and β-catenin signaling.

Authors:  Zhengxi Wei; Zahir A Shaikh
Journal:  Toxicol Appl Pharmacol       Date:  2017-05-17       Impact factor: 4.219

3.  BHX, a novel pyrazoline derivative, inhibits breast cancer cell invasion by reversing the epithelial-mesenchymal transition and down-regulating Wnt/β-catenin signalling.

Authors:  Hanmei Bao; Qing Zhang; Zhongling Zhu; Hui Xu; Fengxia Ding; Meisa Wang; Shuangshuang Du; Yibo Du; Zhao Yan
Journal:  Sci Rep       Date:  2017-08-22       Impact factor: 4.379

4.  Circular RNA 0001073 Attenuates Malignant Biological Behaviours in Breast Cancer Cell and Is Delivered by Nanoparticles to Inhibit Mice Tumour Growth.

Authors:  Ziying Yi; Yunhai Li; Yushen Wu; Beilei Zeng; Hongzhong Li; Guosheng Ren; Xiaoyi Wang
Journal:  Onco Targets Ther       Date:  2020-06-29       Impact factor: 4.147

Review 5.  Effects of radiation on the metastatic process.

Authors:  Nora Sundahl; Fréderic Duprez; Piet Ost; Wilfried De Neve; Marc Mareel
Journal:  Mol Med       Date:  2018-04-24       Impact factor: 6.354

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.